Research Head and Neck Cancer Clinical Trials
A crucial challenge in cancer research is figuring out how to make immunotherapies more effective, channeling, and selectively guiding the body’s own immune responses in targeting and killing tumors.
Rachel Sauer | 
September 21, 2021
Research Honors Head and Neck Cancer Magazine Funding
Research and treatment of head and neck cancers at the University of Colorado Cancer Center reached a new level this month with a highly competitive Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). The SPORE was approved by NCI Scientific Program leadership for FY2021 funding; the projected starting date is July 1
Greg Glasgow | June 07, 2021
Not all cancerous tumors are created equal. Some tumors, known as “hot” tumors, show signs of inflammation, which means they are infiltrated with T cells working to fight the cancer. Those tumors are easier to treat, as immunotherapy drugs can then amp up the immune response.
Greg Glasgow | April 22, 2021
Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
Valerie Gleaton | April 16, 2021
Studies have long reported that Black cancer patients have poorer outcomes than their white counterparts. But two University of Colorado Cancer Center researchers decided to investigate the data further and figure out why. What they found was that the outcome disparity was caused not by biology, but simply by differences in access to health care.
Cancer Center | October 01, 2020
Research Head and Neck Cancer Cancer Clinical Trials
Nearly two thousand people living in Colorado will be diagnosed with head and neck cancer (HNC) in 2020. Generally, a very aggressive disease, head and neck cancer require expert care that is not widely available in community cancer clinics. However, patients that are not well-represented in clinical studies, especially Hispanic patients, are less likely to get care from centers that specialize in the disease, such as the University of Colorado Cancer Center.
Cancer Center | June 29, 2020
Research Faculty Head and Neck Cancer
If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drug’s effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies. That’s because tumors from human cancer samples can only grow in mice with suppressed immune systems. Immunotherapies activate the immune system against cancer. And in a mouse model in which the immune system has been suppressed, there is no immune system to activate against cancer.
Garth Sundem | August 23, 2018
Nearly 12,000 people will die of head and neck cancer in the United States this year and worldwide cases will exceed half a million.
Garth Sundem | January 26, 2012
5280
January 05, 2022
CU Cancer Center member Neil Box, MD, separates fact from pseudoscience when it comes to protecting yourself from the sun.
Denver 7
December 23, 2021
In 2021, a Crested Butte family received a life-changing diagnosis. During the holiday season, their story is an apparent reminder that sometimes the best gifts are never found under a tree.
Cure Today
December 15, 2021
A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.
Healio
December 11, 2021
Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.
